The annual call for new topics in now open
We welcome you to propose a new health condition for a screening programme that is not already considered by the UK NSC.
Please download the form and read the guidance at the end of this link to make a proposal.
The deadline for submissions is 16th December 2018. For more information please see this blog.

The UK NSC recommendation on Gaucher disease screening in newborns

Recommendation Systematic population screening programme not recommended
Last review completed January 2015
Next review due in 2017/18
Key downloads

Find general information about population health screening.

Why is screening not recommended by UK NSC?

National universal screening for Gaucher disease was not recommended because there are a number of uncertainties with Gaucher disease; specifically around predicting how severely an individual, detected through screening, might be affected by the condition. It is not currently possible to identify who will be severely affected by the condition and who will never experience any problems.

It is unclear whether earlier treatment following a screening test would be more beneficial than current medical practice of identification and treatment when symptoms develop.

More about Gaucher disease

Gaucher disease is the most common of a group of conditions called lysosomal storage diseases. It is a rare inherited condition caused by a faulty or missing enzyme (a chemical found naturally in the body) used to break down fatty substances from cells. The part of certain cells affected is called the lysosome and the condition leads to the build-up of a fatty substance in cells and organs that become swollen.

The age and severity of symptoms for people with Gaucher disease vary significantly but typical symptoms include bruising, fatigue, low levels of substances needed in the blood (iron and platelets) and enlarged organs such as the liver, spleen, bone and lungs.

If left untreated the condition can cause multiple problems and in rare, more severe cases can be fatal for newborn babies and infants. There is no cure for the condition but the most common treatment is enzyme replacement therapy and this can often limit the effects of Gaucher disease. 

» For more information on Gaucher Disease visit the Contact a Family website


British Association of Perinatal Medicine
British Inherited Metabolic Disease Group
Children Living with Inherited Metabolic Diseases
Faculty of Public Health
Gauchers Association
Genetic Alliance UK
MPS Society
Royal College of General Practitioners
Royal College of Midwives
Royal College of Paediatrics and Child Health
Royal College of Physicians
Royal College of Physicians and Surgeons of Glasgow
Royal College of Physicians of Edinburgh
Save Babies Through Screening Foundation UK

The stakeholder groups will be involved when the recommendation is next reviewed. If you think your organisation should be added, please contact us. More information for stakeholders can be found in appendix C of the UK NSC evidence review process.

Related documents

icon Ethical, Social and Legal Issues with Expanding the Newborn Blood Spot Programme (PDF document, 2.13MB, 21/08/14)

More options

Go to top